{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

A survey to assess the usage pattern of duloxetine in the management of diabetic peripheral neuropathy in India

Survey Questionnaire Form
Doctor’s details
@if(isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. How many patients of peripheral neuropathic pain do you see in a month? *

  2. From your clinical experience, mention the most common type of peripheral neuropathic pain that patients present to you at diagnosis? *

  3. Do you consider duloxetine as a first-line treatment for diabetic peripheral neuropathy? *

  4. What percentage of your diabetic peripheral neuropathy patients achieve satisfactory symptom relief with duloxetine alone? *

  5. In your practice, what proportion of diabetic peripheral neuropathy patients require combination therapy involving duloxetine? *

  6. What percentage of your diabetic peripheral neuropathy patients are currently prescribed duloxetine treatment? *

  7. In your experience, how effective do you find duloxetine in managing diabetic peripheral neuropathy symptoms? *
  8. On a scale of 1 to 5, How satisfied are you with the current dosing options available for duloxetine? (5 being very satisfied) *

  9. What is your typical starting dose of duloxetine in diabetic peripheral neuropathy patients? *

  10. In your experience, how quickly do patients typically respond to duloxetine treatment? *

  11. Which factors are critical for choosing duloxetine in managing diabetic peripheral neuropathy? *
  12. How often do you adjust the dosage of duloxetine for optimal symptom management? *

  13. On average, how long do your patients remain on duloxetine treatment? *

  14. In your experience, does duloxetine provide long-term benefits for diabetic peripheral neuropathy patients? *

  15. Have you observed any differences in treatment response based on patient’s age when prescribing duloxetine in diabetic peripheral neuropathy patients? *

  16. Have you observed any differences in treatment response based on patient’s gender when prescribing duloxetine in diabetic peripheral neuropathy patients? *

  17. What percentage of your patients report satisfactory compliance with duloxetine treatment? *

  18. How do you typically monitor the effectiveness of duloxetine treatment in your patients? *

  19. How satisfied are your patients with the response of the duloxetine in managing their diabetic peripheral neuropathic pain? (5 being very satisfied) *

  20. How satisfied are your patients with the tolerability of duloxetine in managing their diabetic peripheral neuropathic pain? (5 being very satisfied) *

  21. In your experience, what are the different types of peripheral neuropathic pain where duloxetine is more effective and why? *
  22. In your experience, what benefits of duloxetine are seen compared to other drugs while treating diabetic peripheral neuropathy in geriatric patients? *
  23. What percentage of patients are satisfied with tolerance to duloxetine? *

  24. How do you assess the long-term efficacy of duloxetine in managing diabetic peripheral neuropathic pain? *
  25. What percentage of your neuropathy patients experience significant improvement in quality of life with duloxetine? *

  26. What percentage of your patients with peripheral neuropathic pain have comorbidities that influence your decision to prescribe duloxetine? *

  27. Based on your experience, do you think additional research is needed to better understand duloxetine in peripheral neuropathy management? *

  28. In your opinion, what advantage does duloxetine offer over other medications in peripheral neuropathy management? *
  29. How would you rate your overall experience with prescribing duloxetine in neuropathy management? (5 being very satisfied) *

  30. How do you adjust the treatment plan based on the disease progression? *